Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32352535    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32352535  :  Publisher
PDF vom PMID32352535

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options #MMPMID32352535
  • Guzik TJ; Mohiddin SA; Dimarco A; Patel V; Savvatis K; Marelli-Berg FM; Madhur MS; Tomaszewski M; Maffia P; D'Acquisto F; Nicklin SA; Marian AJ; Nosalski R; Murray EC; Guzik B; Berry C; Touyz RM; Kreutz R; Wang DW; Bhella D; Sagliocco O; Crea F; Thomson EC; McInnes IB
  • Cardiovasc Res 2020[Aug]; 116 (10): 1666-1687 PMID32352535show ga
  • The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
  • |*Coronavirus Infections/diagnosis/drug therapy[MESH]
  • |*Myocarditis/diagnosis/drug therapy/virology[MESH]
  • |*Pandemics[MESH]
  • |*Pneumonia, Viral/diagnosis/drug therapy[MESH]
  • |Angiotensin-Converting Enzyme Inhibitors/*pharmacology[MESH]
  • |Betacoronavirus/*pathogenicity[MESH]
  • |Humans[MESH]
  • |Renin-Angiotensin System/drug effects[MESH]
  • |Risk Assessment[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1666 10.116 2020